Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Neurocrine Biosciences, Inc.
NBIX
NASDAQ·Healthcare·Biotechnology·Mkt cap $16.9B
$172.02
▲ +2.53%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$122.14 - $172.41
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 29.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Market-leading INGREZZA with strong tardive dyskinesia franchise and brand recognition
- Diversified product portfolio across multiple therapeutic areas reducing revenue concentration risk
- Strategic partnerships with major pharmaceutical companies providing development and commercialization support
- Experienced management team with proven track record in specialty pharmaceutical development and commercialization
- Focused pipeline targeting high-value indications with significant unmet medical needs
Bear Case
2 risks
- Low volatility (beta 0.4).
- Growth premium of 1.6x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Growth
Stable outlook
Strong revenue growth (21% YoY)
Value
Growth premium of 1.6x vs Large Cap Pharma peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+27.5% over 3m
Quality
Excellent
High-growth business (29% revenue growth, 98% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying NBIX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 4, 2026
MAY 5, 2026
Reported EPS of $1.94 vs $1.68 consensus (+15.5% surprise). Revenue of $814.5M vs $768.3M expected (+6.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+15.5%
Next: May 4, 2026
Revenue trend · last 8Q
—
—
+22%
+11%
+16%
+28%
+28%
+42%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$590.2M
$622.1M
$627.7M
$572.6M
$687.5M
$794.9M
$805.5M
$814.5M
Margins · last 8Q
Gross
—
Operating
—
Profit
24.3%
Wall Street consensus
14 analysts · 86% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
86%
Hold
14%
Sell
0%
Median Price Target
$220.00
▲ +27.9% vs $172.02
Latest: Goldman Sachs · $213.00 · Jun 2, 2026
4 analysts covering
vs Industry
How NBIX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related